Streetbeat News

NRXP

NRx Pharmaceuticals, Inc.

https://www.nrxpharma.com

Industry

Biotechnology

NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-100 and NRX-101 oral therapeutics for the treatment of bipolar depression in patients with acute suicidal behavior/ideation and sub-acute suicidal ideation and behavior. The company was founded in 2015 and is based in Wilmington, Delaware.

Open

1.24

Mkt cap

15M

Volume

80K

High

1.27

P/E Ratio

-0.60

52-wk high

7.33

Low

1.21

Div yield

N/A

52-wk low

1.10

NRx Pharmaceuticals has announced a 1-for-10 reverse stock split in an effort to maintain its Nasdaq listing. This corporate action is a strategic move to comply with Nasdaq's minimum bid price requirement.

Portfolio Pulse from Benzinga Newsdesk

March 28, 2024 | 12:03 pm

Earnings reports for March 28, 2024, include a mix of expected profits and losses across various sectors. Notable companies like Walgreens Boots Alliance and MSC Industrial Direct Co anticipate earnings, while others like Shimmick and Affimed project losses. The diversity of industries, from healthcare to technology and finance, highlights the varied performance within the market.

Portfolio Pulse from Benzinga Insights

March 28, 2024 | 9:24 am

NRX Pharmaceuticals (NASDAQ:NRXP) is scheduled to release its quarterly earnings report on March 28, 2024, with analysts expecting an EPS of $-0.07. The company's past performance shows a pattern of beating EPS estimates, leading to positive share price movements the following day. However, shares have declined 27.21% over the last 52 weeks, indicating long-term shareholder dissatisfaction. Investors will be keenly watching for not only the earnings results but also the company's guidance for future growth.

Portfolio Pulse from Benzinga Insights

March 27, 2024 | 5:01 pm

NRx Pharmaceuticals announced plans to distribute shares of HOPE Therapeutics and royalty rights on Ketamine sales to its existing shareholders, causing its shares to trade higher.

Portfolio Pulse from Benzinga Newsdesk

March 18, 2024 | 3:16 pm

NRx Pharmaceuticals plans to distribute 49% of HOPE Therapeutics stock and a 1% royalty right on Ketamine sales to its shareholders. The Board of Directors has authorized necessary steps to effectuate this dividend and royalty rights distribution, pending completion of legal, accounting, and regulatory requirements.

Portfolio Pulse from Benzinga Newsdesk

March 18, 2024 | 12:35 pm

Asana, Inc. (ASAN) shares fell by 11% following soft FY25 revenue guidance, despite beating quarterly earnings and sales estimates. Other stocks showed significant movement, with ClearOne, Inc. (CLRO) and Regulus Therapeutics Inc. (RGLS) among the top gainers, while BYND Cannasoft Enterprises Inc. (BCAN) and Simpple Ltd. (SPPL) led the losers. The market saw a mix of positive and negative financial results, strategic moves, and guidance updates.

Portfolio Pulse from Avi Kapoor

March 12, 2024 | 6:07 pm

In Tuesday's intraday session, several healthcare stocks experienced significant movements. Regulus Therapeutics (RGLS) led the gainers with a 94.9% increase, while Lexaria Bioscience (LEXX) saw the largest decline at 30.5%. Other notable movers included Bright Green (BGXX), SCWorx (WORX), and Caribou Biosciences (CRBU), among others. The movements were attributed to various factors, including quarterly earnings reports for Viracta Therapeutics (VIRX) and Caribou Biosciences.

Portfolio Pulse from Benzinga Insights

March 12, 2024 | 5:31 pm

NRx Pharmaceuticals is considering a reverse stock split to maintain its NASDAQ listing compliance, leading to a decrease in its share price.

Portfolio Pulse from Benzinga Newsdesk

March 12, 2024 | 4:30 pm

Nasdaq Composite gained around 1% amid positive U.S. stock market movements. ClearOne, Inc. announced a special cash dividend, causing shares to surge 120%. Regulus Therapeutics and Ranpak Holdings also saw significant gains following positive announcements. Conversely, BYND Cannasoft, Blade Air Mobility, and NRx Pharmaceuticals experienced sharp declines due to various negative developments. The U.S. consumer price index for February 2024 indicated higher-than-expected inflation rates.

Portfolio Pulse from Avi Kapoor

March 12, 2024 | 4:10 pm

U.S. stocks traded higher with the Dow gaining 0.27% and the Nasdaq up by 0.69% amid news of U.S. inflation rate rising to 3.2% in February, surpassing expectations. ClearOne, Regulus Therapeutics, and Ranpak Holdings reported significant stock movements due to corporate announcements, while BYND Cannasoft, Blade Air Mobility, and NRx Pharmaceuticals saw declines.

Portfolio Pulse from Avi Kapoor

March 12, 2024 | 2:11 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.